Market Overview

Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc., NCR Corporation And BP plc

Related MRK
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
FDA Decisions In November: The Month In Review
FDA accepts Merck's marketing application for Keytruda for type of lymphoma; shares up 2% (Seeking Alpha)

CNBC Fast Money's Pete Najarian recommended a long position in Merck & Co., Inc. (NYSE: MRK). The stock traded 1.1 percent lower to around $59.

Jon Najarian thinks that NCR Corporation (NYSE: NCR) is buy. NCR Corporation jumped 1.7 percent.

Jim Lebenthal is a buyer of BP plc (ADR) (NYSE: BP), which recovered from early losses and gained almost 1 percent in the afternoon session.

Posted-In: Jim Lebenthal Jon Najarian Pete NajarianCNBC Fast Money Media


Related Articles (BP + MRK)

View Comments and Join the Discussion!

Partner Center